Major boost for rheumatoid arthritis drug development

October 26, 2005

The first spin-out company from Perth's Telethon Institute for Child Health Research has achieved national recognition with a prestigious AusIndustry grant worth $2.27 million.

The funding to Phylogica reflects the exciting potential of the new drug technology being developed by the company, which was listed on the Australian Stock Exchange in March.

Institute Director, Professor Fiona Stanley, said the grant reflects the quality and novelty of the science behind the new drug delivery platform. "This is a great endorsement of the scientific excellence that underpins Phylogica," Professor Stanley said.

"Our aim is always to see our research translated into real benefits to the community and the grant will certainly accelerate the path to commercialisation."

Phylogica's Phylomer® technology is an alternative to conventional antibody-based therapies and can be manufactured at a much lower cost. The AusIndustry funding will be used to progress promising drugs for Rheumatoid Arthritis to clinical trial.

Phylomers® are stable fragments of naturally-occurring proteins with the ability to bind tightly to target proteins and inactivate them as a result. Phylomers® can be selected for activity against specific disease target proteins.

"While Rheumatoid Arthritis will be the first disease area targeted, we're hopeful that the Phylomer® technology will provide new therapies for a wide range of diseases including asthma and type two diabetes," Professor Stanley said.
-end-
Media contact:
Elizabeth Chester
+61 409 988 530 (mobile)
Telethon Institute for Child Health Research
www.ichr.uwa.edu.au

Research Australia

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.